Tue, May 13, 12:02 PM (41 days ago)
**Monopar Therapeutics Inc. (MNPR) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue generated; the company is in the clinical-stage. - **Profit Margins:** Operating loss of $3.22 million, up from $1.72 million in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $5.66 million, up from $1.66 million in Q1 2024. - **Earnings Changes:** Net loss of $2.62 million, compared to $1.64 million in Q1 2024. - **Cash Position:** $39.71 million in cash and cash equivalents as of March 31, 2025, down from $45.82 million in December 2024. **Key Metrics and Trends:** - **Operating Expenses:** Increased by 88% to $3.22 million, driven by higher R&D and G&A expenses. - **R&D Expenses:** Increased by 69.9% to $1.64 million, primarily due to clinical trial activities. - **G&A Expenses:** Increased by 108.7% to $1.58 million, due to higher stock-based compensation and legal fees. - **Interest Income:** Increased by 603% to $597,000, due to higher cash balances. **Quarterly Performance Discussion:** - The company is focused on developing ALXN1840 for Wilson disease and radiopharmaceutical programs (MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac). - Management expects current funds to be sufficient through December 31, 2026. - The company is preparing to submit an NDA for ALXN1840 in early 2026. - Radiopharmaceutical programs are progressing with ongoing clinical trials. **Uncertainties and Future Operations:** - The company faces significant risks related to clinical trial outcomes, regulatory approvals, and funding. - Future operations depend on successful clinical trials, regulatory approvals, and securing additional funding. - The company may need to raise additional capital through equity offerings, debt financing, or strategic partnerships. **Impact on Future Operations:** - The company's ability to advance its product pipeline and achieve regulatory approvals will depend on its financial resources and operational execution. - Successful clinical trials and regulatory approvals could lead to significant revenue growth and improved financial performance. - Failure to secure additional funding or achieve regulatory approvals could negatively impact the company's operations and financial health.